- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Cytogen secures financing package
Monoclonal antibody developer Cytogen last month entered into a financing deal with Nomura SecuritiesInternational. Under the agreement, Cytogen, of Princeton, NJ,could sell up to $49 million of its common stock to Nomura fordistribution in public
Monoclonal antibody developer Cytogen last month entered into a financing deal with Nomura SecuritiesInternational. Under the agreement, Cytogen, of Princeton, NJ,could sell up to $49 million of its common stock to Nomura fordistribution in public markets. The sales will be made in a seriesof transactions over the next two years. Cytogen will use thefinancing to pursue strategic alliances and broaden its productpipeline, according to Thomas McKearn, Cytogen president and CEO.
Also last month, Cytogen announced that the Food and Drug Administrationhas accepted its product license application (PLA) for ProstaScint,a monoclonal antibody-based imaging agent for detection of prostatecancer (SCAN 2/1/95).
European Society of Breast Imaging Issues Updated Breast Cancer Screening Recommendations
April 24th 2024One of the recommendations from the European Society of Breast Imaging (EUSOBI) is annual breast MRI exams starting at 25 years of age for women deemed to be at high risk for breast cancer.
Study Reveals Benefits of Photon-Counting CT for Assessing Acute Pulmonary Embolism
April 23rd 2024In comparison to energy-integrating detector CT for the workup of suspected acute pulmonary embolism, the use of photon-counting detector CT reduced radiation dosing by 48 percent, according to newly published research.
Could a Newly FDA-Cleared C-Arm Device Bolster Efficiency for Interventional Radiologists?
April 22nd 2024In addition to advanced imaging quality and dose efficiency, the Philips Zenition 30 mobile C-arm device emphasizes personalized user profiles and automated customization to help reduce procedure time.
